Vertex Pharmaceuticals Competitors

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vertex Pharmaceuticals and Amgen, as reported by MarketBeat.

Vertex Pharmaceuticals currently has a consensus target price of $292.68, indicating a potential upside of 38.07%. Amgen has a consensus target price of $257.2174, indicating a potential upside of 12.95%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Profitability

This table compares Vertex Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Amgen's revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Amgen on 11 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Volatility & Risk

Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Gilead Sciences and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Gilead Sciences currently has a consensus price target of $96.0370, indicating a potential upside of 48.62%. Vertex Pharmaceuticals has a consensus price target of $292.68, indicating a potential upside of 38.07%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Vertex Pharmaceuticals.

Earnings & Valuation

This table compares Gilead Sciences and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Vertex Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Gilead Sciences on 9 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings for Regeneron Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus target price of $625.8077, suggesting a potential upside of 35.58%. Vertex Pharmaceuticals has a consensus target price of $292.68, suggesting a potential upside of 38.07%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Vertex Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Vertex Pharmaceuticals currently has a consensus target price of $292.68, suggesting a potential upside of 38.07%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 12.47%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Biogen.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Biogen's revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Vertex Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Biogen on 10 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Alexion Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.

Alexion Pharmaceuticals currently has a consensus price target of $155.00, suggesting a potential upside of 3.26%. Vertex Pharmaceuticals has a consensus price target of $292.68, suggesting a potential upside of 38.07%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Seagen and Vertex Pharmaceuticals, as provided by MarketBeat.

Seagen currently has a consensus price target of $188.4615, indicating a potential upside of 26.19%. Vertex Pharmaceuticals has a consensus price target of $292.68, indicating a potential upside of 38.07%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Seagen.

Risk & Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Seagen and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Seagen on 10 of the 14 factors compared between the two stocks.